NEW YORK (GenomeWeb News) – Investment bank Cowen & Co. today upgraded PerkinElmer's stock, citing favorable end-market exposure and year-over-year comparisons that could result in mid-single digit revenue growth in 2014.

Analyst Doug Schenkel upgraded the company's stock to Outperform from Market Perform, and increased the price target on its shares to $47 from $35.20.

In afternoon trading on Monday, PerkinElmer's shares on the Nasdaq was up 1 percent to $41.68.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.

The Associated Press reports that gene-edited food may soon be for sale.

The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.

In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.